Filing Flows › Johnson & Johnson (JNJ) › Q3 2026
Johnson & Johnson (JNJ) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 21, 2026
Johnson & Johnson (JNJ) reported revenue of $25.4B for the third quarter 2026 (Q3 2026), +6% from a year earlier and +0.4% from the quarter before. Operating margin was 0.1%, net earnings $210M (0.8% of revenue).
Johnson & Johnson, Q3 2026: revenue $25.4B (+6% year over year), operating margin 0.1%, net earnings $210M, operating cash flow $7.7B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25.4B | +0.4% | +6% |
| Gross profit | $17.3B | +0.2% | +4% |
| Operating profit | $34.0M | -99% | -100% |
| Net earnings | $210M | -96% | -96% |
| Operating cash flow | $7.7B | -10% | -16% |
| Free cash flow | $6.4B | -13% | -21% |
What changed
Revenue was $25.4B in Q3 2026, up 6% year over year and roughly flat from the previous quarter. Innovative Medicine was the largest line at 66% of revenue. Innovative Medicine added $1.2B year over year (up 8%), 85% of the total change.
Gross margin was 68.1%, down 1.4 points from Q3 2025. Operating profit was $0.03B, a 0.1% margin (down 31.1 points year over year). Operating profit fell $7.5B even though revenue rose $1.4B versus Q3 2025, so costs grew faster than sales. Operating expenses grew 88% against revenue growth of 6%. Net earnings were $0.21B, down 96% year over year. The tax line was a benefit of $0.18B on pre-tax earnings of $0.03B.
Operating cash flow was $7.7B (down 16% year over year), 3676% of net earnings. Non-cash charges added back $2.1B of depreciation and amortization and $0.36B of share-based compensation. Working capital and other items added $5.0B. Capital expenditures of $1.4B left free cash flow of $6.4B.
Questions
What was Johnson & Johnson's revenue in the third quarter 2026?
Johnson & Johnson (JNJ) reported revenue of $25.4B for the third quarter 2026 (Q3 2026), +6% from a year earlier and +0.4% from the quarter before.
Was Johnson & Johnson profitable in the third quarter 2026?
Operating profit was $34.0M (0.1% of revenue) and net earnings $210M.
Source: Johnson & Johnson 10-Q on SEC EDGAR.